Immunogenicity and safety of SARS-CoV-2 (COVID-19 virus) vaccine in patients with hepatocellular carcinoma
- Conditions
- Immunogenicity and safety of SARS-CoV-2 vaccine in patients with hepatocellular carcinomaCOVID-19, vaccine, hepatocellular carcinoma, SARS-CoV-2
- Registration Number
- TCTR20210525005
- Lead Sponsor
- Faculty of Medicine, Chulalongkorn university
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending (Not yet recruiting)
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Patients with hepatocellular carcinoma
Exclusion Criteria
1. Anaphylaxis to SARS-CoV-2 vaccine
2. Pregnancy or lactation
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Immunogenicity of SARS-CoV-2 vaccine 6 months SARS-CoV-2 antibody
- Secondary Outcome Measures
Name Time Method Safety of SARS-CoV-2 vaccine 6 months Patient reported adverse events